Abstract
We conducted a clinical pilot study to evaluate the efficacy and safety of the combination of docetaxel and 5′DFUR as a second-line chemotherapy for gastric cancer. Twenty-four patients were divided into two groups by simple randomization: group A (60 mg/m2 of docetaxel, every 3 wk) and group B (regimen A + 600 mg/body of 5′DFUR). The response rate was 17% and 42% in group A and B, respectively (p<0.05). The MST from the start of the first-line was 17 mo in group B. The major adverse event was leukopenia in both groups.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Ferlay J, Bray F, Pisani P, Parkin DM. Globocan 2000. Cancer incidence, mortality and prevalence worldwide, version 1.0. IARC CancerBase No. 5 IARCPress, Lyon, France, 2001.
Murad AM, Santiago FF, Petroianu A, Petroianu A, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer. Cancer 1993; 72: 37–41.
Altinbas M, et al. Irinotecan plus cisplatin combination against metastatic gastric cancer: phase II study. Med Oncol 2005; 22: 153–160.
Kunisaki C, et al. Phase II study of docetaxel plus cisplatin as a second-line combined therapy in patients with advanced gastric cancer. Anticancer Res 2005; 25: 2973–2978.
Ishizone S, et al. Efficacy of S-1 for patients with peritoneal metastasis of gastric cancer. Chemotherapy, 2006; 52: 301–307.
Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 1998; 4: 1013–1019.
Graziano F, et al. A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. Ann Oncol 2000; 11: 1263–1266.
Wilson D, Hiller L, Geh JI. Review of second-line chemotherapy for advanced gastric adenocarcinoma. Clini Oncol 2005; 17: 81–90.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Maruta, F., Ishizone, S., Hiraguri, M. et al. A clinical study of docetaxel with or without 5′DFUR as a second-line chemotherapy for advanced gastric cancer. Med Oncol 24, 71–75 (2007). https://doi.org/10.1007/BF02685905
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02685905